Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Enrollment begins for phase III study of central precocious puberty implant

Sep. 13, 2004

CKD-501 reduces glucose levels in model of insulin resistance

Sep. 13, 2004

Phase II Hemospan study opens in Sweden

Sep. 13, 2004

Two series of glucokinase activators presented by Lilly scientists

Sep. 13, 2004

Clinical efficacy of repaglinide discussed at European Diabetes Congress

Sep. 13, 2004

Studies assess metformin combination therapies in type 2 diabetes

Sep. 13, 2004

New, potent alphavbeta3 antagonists selected for clinical evaluation for osteoporosis at Merck

Sep. 10, 2004

L-2264 improves hyperglycemia, lipids in animal model of diabetes

Sep. 10, 2004

Clinical evidence supports the antidiabetic efficacy of MK-0431 in humans

Sep. 10, 2004

U.S./Canadian pivotal study commences for icatibant in hereditary angioedema

Sep. 10, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...